Maravai (MRVI) Form 4 Shows 89k-Share RSU Grant to Board Member

Rhea-AI Filing Summary

Form 4 filed for Maravai LifeSciences Holdings, Inc. (MRVI) discloses that director Jessica Hopfield received 89,139 Class A common-stock restricted stock units (RSUs) on 16 June 2025 under the company’s 2020 Omnibus Incentive Plan. The RSUs will vest in full on the earlier of one year from the grant date or the 2026 annual stockholders’ meeting. Following the award, Hopfield now reports 199,907 shares held directly. Transaction code “A” confirms the award was an acquisition, not an open-market purchase or sale. No derivative securities were involved, and there were no dispositions. Overall, the filing represents a routine equity incentive grant aligning director compensation with shareholder interests.

Insights

Corporate Governance Expert

TL;DR: Routine RSU grant; neutral governance signal.

The Form 4 shows a standard annual equity award to a non-employee director, increasing direct holdings without cash outflow. Such grants are customary for U.S. public companies and aim to align board incentives with long-term shareholder value. The size—89,139 RSUs at $2.16 reference value—is modest relative to Maravai’s market cap and does not suggest insider conviction beyond normal compensation. No sales or derivative exercises were reported, so there is no negative liquidity signal. Investors typically view this as neutral; it neither materially improves nor harms the investment thesis.

Insider Trade Summary

Net Buyer: 89,139 shares

Net Buy 1 txn

Insider Hopfield Jessica

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	89,139	$2.16	$193K

Holdings After Transaction: Class A Common Stock — 199,907 shares (Direct)

Footnotes (1)

1. F1. Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on June 16, 2025, which vest in full upon the earlier of one year from the date of grant or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

FAQ

How many MRVI shares did Jessica Hopfield acquire in the latest Form 4?

The filing reports an award of 89,139 Class A common-stock RSUs to director Jessica Hopfield.

What is the total number of MRVI shares Jessica Hopfield now owns?

After the reported transaction, Hopfield lists 199,907 shares held directly.

When do the newly granted MRVI RSUs vest?

The RSUs vest in full on the earlier of one year from 16 Jun 2025 or the 2026 annual meeting.

Was the MRVI transaction an open-market purchase or a grant?

Transaction code “A” indicates it was an equity grant (acquisition), not an open-market trade.

Did the Form 4 include any derivative security activity for MRVI?

No. No derivative securities were acquired or disposed of in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 06/18/2025 - 06:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopfield Jessica

(Last) (First) (Middle)

C/O MARAVAI LIFESCIENCES HOLDINGS, INC.

10770 WATERIDGE CIRCLE, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/16/2025		A		89,139(1)	A	$2.16	199,907	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on June 16, 2025, which vest in full upon the earlier of one year from the date of grant or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Remarks:

	/s/ Kurt Oreshack, by power of attorney for Jessica Hopfield	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.